Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
Healthcare
$16.62 +0.58%
+$0.04 today
- Market cap
- $3.04B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
52W Low $4.40High $10.08
Volume 2.56M
Average 1.66M
Income Statement
Follow revenue through to earnings.
Revenue
$291.85M
FY 2025 · Annual
+43.7% YoYOperating Income
$24.90M
FY 2025 · Annual
Net Income
$554,000.00
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.59M | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | 13.32M | 22.63M | 28.65M | 36.83M | 53.41M |
| Gross Profit | 36.27M | 87.61M | 135.27M | 166.24M | 238.43M |
| Gross Margin | 73.1% | 79.5% | 82.5% | 81.9% | 81.7% |
| Research & Development | 25.16M | 20.97M | 22.34M | 25.56M | 31.17M |
| Selling, General & Admin | 125.72M | 137.75M | 146.1M | 163.48M | 182.37M |
| Operating Expenses | 151.43M | 169.55M | 179.28M | 199.88M | 213.54M |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| EBITDA | (113.67M) | (69.31M) | (23.74M) | (13.99M) | 12.71M |
| EBITDA Margin | -229.2% | -62.9% | -14.5% | -6.9% | 4.4% |
| Operating Income | (115.16M) | (81.94M) | (44.01M) | (33.65M) | 24.9M |
| Operating Margin | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Interest Income | 313K | 2.58M | 4.75M | 5.32M | 4.74M |
| Interest Expense | 7.18M | 14.1M | 26.61M | 33.18M | 29.08M |
| Other Income / Expenses | (7.57M) | (14.14M) | (19.49M) | (23.46M) | (24.34M) |
| Income Before Tax | (122.73M) | (96.08M) | (63.5M) | (57.1M) | 554K |
| Pre-Tax Margin | -247.5% | -87.2% | -38.7% | -28.1% | 0.2% |
| Income Tax Expense | 0 | (1.42M) | (1.25M) | (2.27M) | 0 |
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Net Margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
| EPS (Basic) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| EPS (Diluted) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| 79.03M | 135.63M | 137.67M | 146.77M | 160.43M | |
| 79.03M | 135.63M | 137.67M | 146.77M | 172.74M |
XERS Earnings Waterfall · TTM
NASDAQ:XERS · Revenue to Net Income
Key Ratios
EPS$0.07
Gross Margin81.6%
Net Margin3.4%
P/E Ratio156.9
P/S Ratio14.2
Analysis
$314.9M of revenue converted into $12.0M of net income for the selected period. Gross margin is 81.6% and net margin is 3.4%, showing how much revenue survives after costs and taxes. EPS is $0.07, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
How much revenue does XERS generate?
Xeris Biopharma Holdings, Inc. (XERS) reported $291.85M of revenue in fiscal 2025.
Is XERS profitable?
Xeris Biopharma Holdings, Inc. (XERS) reported $554,000.00 of net income, with a net margin of 0.2%.
Continue the stock analysis
Jump to another research area for this company.